Cybin

{{Infobox company

| name = Cybin IRL

| logo = Cybin company logo.jpg

| logo_size = 175px

| logo_caption =

| logo_upright =

| logo_alt =

| type =

| industry = Pharmaceutical; Psychedelic medicine

| predecessor =

| founded = {{Start date and age|2019}}

| founder =

| defunct =

| fate =

| successor =

| hq_location_city = Toronto

| hq_location_country = Canada

| area_served =

| key_people =

| products =

| owner =

| num_employees =

| num_employees_year =

| parent =

| website = {{URL|https://cybin.com/}}

}}

Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.{{cite journal | vauthors = Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L | title = The Therapeutic Potential of Psilocybin | journal = Molecules | volume = 26 | issue = 10 | date = May 2021 | page = 2948 | pmid = 34063505 | pmc = 8156539 | doi = 10.3390/molecules26102948 | doi-access = free | url = }}{{cite journal | last1=Aday | first1=Jacob S. | last2=Barnett | first2=Brian S. | last3=Grossman | first3=Dan | last4=Murnane | first4=Kevin S. | last5=Nichols | first5=Charles D. | last6=Hendricks | first6=Peter S. | title=Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry | journal=Psychedelic Medicine | volume=1 | issue=3 | date=1 September 2023 | issn=2831-4425 | doi=10.1089/psymed.2023.0013 | pages=150–165 | url=https://www.researchgate.net/publication/373171466 | quote=Cybin is currently launching a pilot study of a psilocybin analogue that may produce psychoactive effects for only 4 hours. | pmc=11661494 }}{{cite journal | vauthors = Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST | title = Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders | journal = Drug Discov Today | volume = 28 | issue = 12 | pages = 103818 | date = December 2023 | pmid = 37925136 | doi = 10.1016/j.drudis.2023.103818 | url = https://drive.google.com/file/d/1mztRkW7vJu7KjpE1xKUyZoObWJ5QvEmt/view }}

The company's drug candidates include psilocybin (CYB001),{{Cite web|url=https://adisinsight.springer.com/drugs/800059460|title=Psilocybin - Cybin - AdisInsight|website=adisinsight.springer.com}} CYB002 (discontinued),{{cite web | title=Delving into the Latest Updates on CYB-002 with Synapse | website=Synapse | date=23 January 2025 | url=https://synapse.patsnap.com/drug/a50ed04a46c84387b4c25b086f2182f8 | access-date=31 January 2025}} CYB003 (deuterated psilocin),{{Cite web|url=https://adisinsight.springer.com/drugs/800062409|title=CYB 003 - AdisInsight|website=adisinsight.springer.com}}{{Cite web|url=https://synapse.patsnap.com/drug/dcb535376933495783bad0ae5504a571|title=Delving into the Latest Updates on CYB-003 with Synapse|website=synapse.patsnap.com}}{{cite journal | vauthors = Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, Reichelt A, Hartsel J, Nivorozhkin A, Inamder A, Varty G | title = ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P361. In Vitro and In Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder | journal = Neuropsychopharmacology | volume = 47 | issue = Suppl 1 | pages = 220–370 (271) | date = December 2022 | pmid = 36456694 | pmc = 9714399 | doi = 10.1038/s41386-022-01485-0 | url = https://cybin.com/wp-content/uploads/2023/09/ACNP_2022_CYB003_Poster-1.pdf}}{{cite journal | vauthors = Inamdar A, Morgan M, Krakowsky J, Reichelt A, Canal C, Mueller T, Avery K, Pathare P, Hartsel J, Nivorozhkin A, Varty G, Palfreyman M | title = ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P362. Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder | journal = Neuropsychopharmacology | volume = 47 | issue = Suppl 1 | pages = 220–370 (271–272) | date = December 2022 | pmid = 36456694 | pmc = 9714399 | doi = 10.1038/s41386-022-01485-0 | url = https://cybin.com/wp-content/uploads/2023/09/ACNP-2022-CYB003-Poster-2.pdf}} CYB004 (deuterated dimethyltryptamine (DMT)),{{Cite web|url=https://adisinsight.springer.com/drugs/800062410|title=CYB 004 - AdisInsight|website=adisinsight.springer.com}} CYB005 (deuterated phenethylamine derivative),{{Cite web|url=https://adisinsight.springer.com/drugs/800064373|title=CYB 005 - AdisInsight|website=adisinsight.springer.com}}{{Cite web|url=https://synapse.patsnap.com/drug/a8134884163c4d42b7817e7986708a88|title=Delving into the Latest Updates on CYB-005 with Synapse|website=synapse.patsnap.com}}{{Cite web|url=https://www.bioworld.com/articles/684429-cybin-reports-preclinical-data-on-deuteration-modifications-in-psychedelic-molecules?v=preview|title=| BioWorld|website=www.bioworld.com}} and CYB006.{{cite web | author=Psychedelic Alpha | title=Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement | website=Psychedelic Alpha | date=29 June 2021 | url=https://psychedelicalpha.com/news/cybin-announces-positive-pre-clinical-results-with-multiple-proprietary-psychedelic-molecules-and-adelia-milestone-achievement | access-date=31 January 2025}}{{Cite web|url=https://cybin.com/development-pipeline/|title=Development Pipeline|website=Cybin}} Another drug that the company has developed is CYB210010 (2C-T-TFM).{{cite journal | vauthors = Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A | title = Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist | journal = Journal of Medicinal Chemistry | volume = 67 | issue = 8 | pages = 6144–6188 | date = April 2024 | pmid = 38593423 | doi = 10.1021/acs.jmedchem.3c01961 }}{{cite journal | vauthors = Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, Morgan M, Mueller T, Reichelt A, Pathare P, Stang E, Nivorozhkin A | date = December 2023 | title = ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist | journal = Neuropsychopharmacology | volume = 48 | issue = Suppl 1 | pages = 211–354 (299–299 | doi = 10.1038/s41386-023-01756-4 | pmid = 38040810 | pmc = 10729596 }}{{cite patent | country = WO | number = 2023156450 | url = https://patents.google.com/patent/WO2023156450A1/en | inventor = Nivorozhkin A, JA Hartsel, Canal CE, Salituro FG, Mueller TA, Greene BJ, Belser A, Avery KL, Reichelt AC, Varty GB, Palfreyman M | title = Therapeutic phenethylamine compositions and methods of use | assign = Cybin Irl Limited | pubdate = 24 August 2023 }}

As of January 2025, CYB003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 (psilocybin) to have reached this late stage of clinical development.{{cite journal | vauthors = Peplow M | title = Next-generation psychedelics: should new agents skip the trip? | journal = Nat Biotechnol | volume = 42 | issue = 6 | pages = 827–830 | date = June 2024 | pmid = 38831049 | doi = 10.1038/s41587-024-02285-1 | url = }}{{cite web | author=Michael Haichin | title=Psychedelics Drug Development Tracker | website=Psychedelic Alpha | url=https://psychedelicalpha.com/data/psychedelic-drug-development-tracker | date=2024 | access-date=29 January 2025}}

In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics.{{cite web | author=Cybin Inc. | title=CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings | website=GlobeNewswire News Room | date=14 December 2020 | url=https://www.globenewswire.com/news-release/2020/12/14/2144494/0/en/CYBIN-Closes-Acquisition-of-Adelia-Therapeutics-Bolsters-Scientific-Team-and-Grows-IP-Portfolio-to-7-Patent-Filings.html | access-date=6 February 2025}}